Non-Covalent Reactions Supporting Antiviral Development

Viruses are the current big enemy of the world's healthcare systems. As the small infector causes various deadly diseases, from influenza and HIV to COVID-19, the virus continues to evolve from one type to its mutants. Therefore, the development of antivirals demands tremendous attention and re...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2022-12, Vol.27 (24), p.9051
Main Authors: Nugrahani, Ilma, Susanti, Emy, Adawiyah, Tazkia, Santosa, Safira, Laksana, Agnesya Namira
Format: Article
Language:English
Subjects:
activity
antiviral
Antiviral agents
Antiviral Agents - chemistry
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Chemical bonds
Chemical reactions
Clinical trials
cocrystal
COVID-19
Cytomegalovirus
Disease
Drugs
Engineering
Fever
Hepatitis B
Herpes viruses
HIV
Human immunodeficiency virus
Humans
Immune system
Influenza
multi-component system
NMR
Nuclear magnetic resonance
Pharmaceutical research
Pharmaceuticals
physicochemical character
Physicochemical properties
Polymorphism
Production methods
Public health
Review
salt
Severe acute respiratory syndrome
Viral infections
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Viruses are the current big enemy of the world's healthcare systems. As the small infector causes various deadly diseases, from influenza and HIV to COVID-19, the virus continues to evolve from one type to its mutants. Therefore, the development of antivirals demands tremendous attention and resources for drug researchers around the world. Active pharmaceutical ingredients (API) development includes discovering new drug compounds and developing existing ones. However, to innovate a new antiviral takes a very long time to test its safety and effectiveness, from structure modeling to synthesis, and then requires various stages of clinical trials. Meanwhile, developing the existing API can be more efficient because it reduces many development stages. One approach in this effort is to modify the solid structures to improve their physicochemical properties and enhance their activity. This review discusses antiviral multicomponent systems under the research phase and has been marketed. The discussion includes the types of antivirals, their counterpart compound, screening, manufacturing methods, multicomponent systems yielded, characterization methods, physicochemical properties, and their effects on their pharmacological activities. It is hoped that the opportunities and challenges of solid antiviral drug modifications can be drawn in this review as important information for further antiviral development.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules27249051